Published in Blood Coagul Fibrinolysis on December 01, 1993
Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol (1998) 1.36
Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy. Neoplasia (1999) 0.81
Update on the use of aromatase inhibitors in early-stage breast cancer. Breast Cancer Res (2009) 0.77
The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen. Br J Surg (1968) 10.22
Natural history of postoperative deep-vein thrombosis. Lancet (1969) 5.18
125-I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis. Lancet (1970) 4.48
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Oral contraceptives, antithrombin- III activity, and postoperative deep-vein thrombosis. Lancet (1976) 2.77
Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg (1970) 2.66
Low doses of heparin in prevention of deep-vein thrombosis. Lancet (1971) 2.38
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med (2001) 2.31
Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. Lancet (1972) 2.20
Postoperative deep-vein thrombosis. Effect of intensive prophylaxis. Lancet (1969) 2.09
A physiological study of elastic compression stockings in venous disorders of the leg. Br J Surg (1980) 2.06
Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem (1989) 2.05
The origin of deep vein thrombosis: a venographic study. Br J Radiol (1971) 1.96
Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and arvin. Br Med J (1969) 1.82
Late results of treatment of deep vein thrombosis. Br Med J (1969) 1.77
The origin of thrombi in the deep veins of the lower limb: a venographic study. Br J Surg (1978) 1.65
Sugar intake, serum insulin and platelet adhesiveness in men with and without peripheral vascular disease. Postgrad Med J (1969) 1.63
Cold adaptation and the seasonal distribution of acute myocardial infarction. QJM (1999) 1.62
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br J Haematol (1995) 1.47
Heparin-induced thrombocytopenia thrombosis after cardiac surgery. A case report. Acta Anaesthesiol Scand (2000) 1.44
Late-onset homozygous protein C deficiency. Lancet (1991) 1.43
Lipid peroxides and atherosclerosis. BMJ (1989) 1.41
The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Eur J Vasc Surg (1994) 1.39
Influence of whole blood on standard curve for heparin measurement--possible heparin binding by red cells. Thromb Haemost (1989) 1.39
Lung function test findings in patients with chronic fatigue syndrome (CFS) Aust N Z J Med (1996) 1.39
Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet (1994) 1.39
Fibrinolytic activity and postoperative deep-vein thrombosis. Lancet (1974) 1.39
An objective study of alternative methods of heparin administration. Thromb Res (1980) 1.38
Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet (1976) 1.38
Review of present status of prophylaxis of venous thromboembolism. Proc R Soc Med (1974) 1.37
Myocardial infarction and deep-vein thrombosis. Br Med J (1971) 1.33
Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol (1977) 1.30
Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res (1981) 1.28
Endotoxaemia and renal failure in cirrhosis and obstructive jaundice. Br Med J (1976) 1.25
The changing pattern of venous thromboembolic disease. Haemostasis (1997) 1.23
Graduated, static, external compression of the lower limb: a physiological assessment. Br J Surg (1980) 1.18
Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J Bone Joint Surg Br (1989) 1.18
Deep-vein thrombosis in patients with fractures of the femoral neck. Br J Surg (1972) 1.18
beta-thromboglobulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol (1983) 1.16
Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J (Clin Res Ed) (1982) 1.16
Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum Mutat (1995) 1.12
Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol (1997) 1.11
Detection of deep vein thrombosis: survey and current status. Prog Cardiovasc Dis (1975) 1.11
The problems of thrombosis in the deep veins of the leg. Ann R Coll Surg Engl (1969) 1.11
Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1995) 1.11
Treatment of deep-vein thrombosis with streptokinase. Br J Surg (1969) 1.10
Femoral vein thrombosis and total hip replacement. Br Med J (1977) 1.10
The I 125 -labeled fibrinogen test and phlebography in the diagnosis of deep vein thrombosis. Milbank Mem Fund Q (1972) 1.09
Plasma heparin levels after administration of calcium and sodium salts of heparin. Thromb Res (1976) 1.09
Deep vein thrombosis. Detection and prevention. Circulation (1975) 1.08
The current status of low-dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism. World J Surg (1978) 1.08
The cephalic vein as a peripheral vascular graft. Surg Gynecol Obstet (1969) 1.07
Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol (2000) 1.07
Low dose heparin in the prevention of venous thromboembolism. Rationale and results. Thromb Diath Haemorrh (1975) 1.06
Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol (1999) 1.06
A heparin analogue with specific action on antithrombin III. Lancet (1977) 1.05
Detection of a novel point mutation causing haemophilia A by PCR/direct sequencing of ectopically-transcribed factor VIII mRNA. Hum Genet (1990) 1.04
Ca2+ release from platelet intracellular stores by thapsigargin and 2,5-di-(t-butyl)-1,4-benzohydroquinone: relationship to Ca2+ pools and relevance in platelet activation. Biochem J (1993) 1.04
Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol (1995) 1.03
Venous stasis and deep-vein thrombosis. Br J Surg (1972) 1.03
Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ (1994) 0.99
Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using he substrate, H-D-Phe-Pip-Arg-p-nitroanilide-2HCl. Clin Chim Acta (1977) 0.98
Treatment of deep-vein thrombosis--a random trial. Br J Surg (1968) 0.98
Chronic fatigue syndrome: physical and cardiovascular deconditioning. QJM (1998) 0.98
Evaluation of a chromogenic method for endotoxin measurement. Thromb Res (1980) 0.98
Mercury compounds induce a rapid increase in procoagulant activity of monocyte-like U937 cells. Br J Haematol (1994) 0.97
Generation of reactive oxygen metabolites by phagocytosing endothelial cells. Atherosclerosis (1988) 0.96
Specific binding sites for inositol 1,3,4,5-tetrakisphosphate are located predominantly in the plasma membranes of human platelets. Biochem J (1994) 0.96
1,2-Dioctanoylglycerol but not 1-oleoyl-2-acetylglycerol inhibits agonist-induced platelet responses. Dependence of effects on extent of 45-kDa protein phosphorylation and agonist type. Eur J Biochem (1987) 0.96
Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. A prospective study. Am J Surg (1985) 0.96
Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells. FEBS Lett (1992) 0.95
Prostaglandins and acute pancreatitis--experimental and clinical studies. Br J Surg (1983) 0.95
Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. J Biol Chem (1987) 0.94
Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. Biochem Pharmacol (1984) 0.94
Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion. Lancet (1975) 0.94
Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation (1993) 0.93
Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol (1978) 0.93
Heparin and dihydroergotamine prophylaxis against thrombo-embolism after hip arthroplasty. J Bone Joint Surg Br (1985) 0.92
Prevention of venous thromboembolism. Clin Haematol (1981) 0.92
Activation of pro-urokinase by plasmin: non-Michaelian kinetics indicates a mechanism of negative cooperativity. Arch Biochem Biophys (1989) 0.92
Prophylaxis for postoperative deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine. JAMA (1979) 0.92
Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that resembling the disintegrin elegantin. J Biol Chem (1996) 0.92
Management of venous thromboembolism. J Assoc Physicians India (2007) 0.92
Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg (1985) 0.92
Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer (1992) 0.91
Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. Am J Med (1981) 0.91
Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. Lancet (1977) 0.91
Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res (1978) 0.90
The diagnosis of deep vein thrombosis in the puerperium. J Obstet Gynaecol Br Commonw (1970) 0.90
Prostatectomy and deep-vein thrombosis. Br J Surg (1972) 0.90
beta-Thromboglobulin--a specific marker of in-vivo platelet release reaction. Thromb Haemost (1980) 0.90
Differential effects of the diacylglycerol kinase inhibitor R59022 on thrombin versus collagen-induced human platelet secretion. Biochim Biophys Acta (1988) 0.89
The Limulus test in experimental and clinical endotoxaemia. Br J Surg (1974) 0.89
Storage pool disease of platelets in an infant with thrombocytopenic absent radii (TAR) syndrome simulating Fanconi's anaemia. Haemostasis (1981) 0.89